A jury found McKesson and Cencora liable for $266 million in damages to the city of Baltimore for fueling the opioid crisis.

We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Kontra Investment Xchange’s Substack by ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...

For the week ended Nov. 8, 11 stocks dropped into undervalued territory, meaning their Morningstar Ratings changed to 4 or 5 ...

Recent developments driving growth in this area make the advanced, AI-supported digitization of pharma pipelines inevitable.

Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday at $17.11. Prasad covers the ...

Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.30 per share for the year, up ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

With one interest rate cut in September and more likely on the way, 2025 could be a standout year for consumer spending.

Analyst Jason Gerberry of Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), boosting ...

In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...

Teva Pharmaceutical Industries Limited (NYSE ... We have many opportunities in this pivot to growth strategy to keep growing ...